SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Subscribe to Platinum Performance as of 11/29/24. Get access to powerful investment ...
Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
According to Daily Mail columnist Ephraim Hardcastle, King Charles III is "gently backtracking" and "regretting" Andrew Mountbatten-Windsor's strict banishment. His Majesty, who allegedly tried to ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...
Recursion Pharmaceuticals, Inc. (RXRX) recently received a notable upgrade from JP Morgan analyst Eric Joseph, who shifted his rating to “Overweight” on December 17, 2025. This upgrade comes as the ...
Recent victories by Democratic gubernatorial candidates in New Jersey and Virginia and for seats on the Georgia Public Service Commission have led outlets like Politico to brand the outcomes as the ...
Hi, everyone, and welcome. I'm Najat Khan, Recursion's Chief R&D and Chief Commercial Officer and incoming CEO and President. Let's jump right in. Today is an important moment for Recursion, for our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback